Kirsten Hogg
03 9345 2805
Denosumab is approved for use in osteoporosis. Laboratory research has identified other potential effects, including possibly slowing or stopping breast cell growth. The BRCA-D trial aims to investigate the effects of denosumab on normal breast tissue in patients with BRCA 1 or 2 mutations and to determine if the drug has potential to prevent breast cancer. Breast tissue will be obtained and evaluated before and after the denosumab injections.
Anticipated date that enrolment will close: Ongoing
For more information about this study visit the TransBCR website: https://www.transbcr.org.au